Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Ziv-Aflibercept in Advanced Solid Tumors
NCT02298959Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2015
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors, Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of aflibercept and pembrolizumab in solid tumor, melanoma, renal cell carcinoma (RCC) and 3 more, sponsored by National Cancer Institute. Primary endpoint: Recommended combination dose of ziv-aflibercept and pembrolizumab at 4 weeks. Started Apr 2015; status: active, not recruiting.
02
Drugs
afliberceptpembrolizumab
03
Conditions
solid tumormelanomarenal cell carcinoma (RCC)ovarian cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02298959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02298959.